G i/o -protein-coupled receptors (GPCRs) ubiquitously inhibit neurotransmission, principally via G␤␥, which acts via a number of possible effectors. GPCR effector specificity has traditionally been attributed to G␣, based on G␣'s preferential effector targeting in vitro compared with G␤␥'s promiscuous targeting of various effectors. In synapses, however, G␤␥ clearly targets unique effectors in a receptordependent way to modulate synaptic transmission. It remains unknown whether G␤␥ specificity in vivo is due to specific G␤␥ isoformreceptor associations or to spatial separation of distinct G␤␥ pathways through macromolecular interactions. We thus sought to determine how G␤␥ signaling pathways within axons remain distinct from one another. In rat hippocampal CA1 axons, GABA B receptors (GABA B Rs) inhibit presynaptic Ca 2ϩ entry, and we have now demonstrated that 5-HT 1B receptors (5-HT 1B Rs) liberate G␤␥ to interact with SNARE complex C terminals with no effect on Ca 2ϩ entry. Both GABA B Rs and 5-HT 1B Rs inhibit Ca 2ϩ -evoked neurotransmitter release, but 5-HT 1B Rs have no effect on Sr 2ϩ -evoked release. Sr 2ϩ , unlike Ca 2ϩ , does not cause synaptotagmin to compete with G␤␥ binding to SNARE complexes. 5-HT 1B Rs also fail to inhibit release following cleavage of the C terminus of the SNARE complex protein SNAP-25 with botulinum A toxin. Thus, GABA B Rs and 5-HT 1B Rs both localize to presynaptic terminals, but target distinct effectors. We demonstrate that disruption of SNARE complexes and vesicle priming with botulinum C toxin eliminates this selectivity, allowing 5-HT 1B R inhibition of Ca 2ϩ entry. We conclude that receptor-effector specificity requires a microarchitecture provided by the SNARE complex during vesicle priming.
Introduction
G i/o -protein-coupled receptor (GPCR)-dependent presynaptic inhibition occurs at all synapses, but is mediated by multiple mechanisms directly involved in evoked exocytosis. The most investigated mechanism is a membrane-delimited G␤␥-mediated inhibition of presynaptic Ca 2ϩ entry (Herlitze et al., 1996; Ford et al., 1998; Brown and Sihra, 2008) . G␤␥ might also activate presynaptic G-protein inwardly rectifying channels (Michaeli and Yaka, 2010) and can modulate neurotransmission by directly interacting with the SNARE complex without altering Ca 2ϩ entry (Blackmer et al., 2001; Takahashi et al., 2001; Gerachshenko et al., 2005) . A region of the SNARE complex C terminus provides a target for the Ca 2ϩ sensor synaptotagmin during the induction of exocytosis (Zhang et al., 2002) . G␤␥ competition with Ca 2ϩ -synaptotagmin at this region mediates presynaptic inhibition (Gerachshenko et al., 2005 (Gerachshenko et al., , 2009 Yoon et al., 2007; Wells et al., 2012) . This region of the SNARE complex is also important for vesicle fusion. Cleavage of the C terminus of SNAP-25 with botulinum toxin A (BoNT/A) modifies fusion pore formation (Fang et al., 2008) , and prevents GPCR-mediated inhibition (Gerachshenko et al., 2005; Delaney et al., 2007) . Indeed, Ca 2ϩ -synaptotagmin interaction with the SNARE complex may mediate fusion pore expansion (Lai et al., 2013) .
Mechanisms that target presynaptic Ca 2ϩ channels and those that interact with the SNARE complex signal with G␤␥, but it is unknown whether, or how, G␤␥-selective targeting of closely localized effectors can occur. In the case of 5-HT 1B receptors (5-HT 1B Rs), it has been shown that 5-HT 1B Rs target Ca 2ϩ channels in the calyceal synapse of Held (Mizutani et al., 2006) , but the C terminus of the SNARE complex in lamprey synapses (Gerachshenko et al., 2005) and chromaffin cells (Blackmer et al., 2005) . GABA B Rs inhibit Ca 2ϩ entry in the Calyx synapse of Held (Takahashi et al., 1998 and in hippocampal neurons (Wu and Saggau, 1995) . Other GPCRs also target either SNARE complexes or Ca 2ϩ channels, for example, noradrenergic-a 2A receptors target the SNARE complex in the amygdala (Delaney et al., 2007) , but may modulate Ca 2ϩ channels in sensory neurons (Dunlap and Fischbach, 1978) . Finally, GABA B Rs also inhibit spontaneous neurotransmitter release events independently of Ca 2ϩ (Scanziani et al., 1992; Kabashima et al., 1997) , an effect that was first shown for adenosine at the neuromuscular junction (Silinsky, 1984) and later in cortex (Cox et al., 2000) . However, effects on spontaneous release may not directly involve evoked release (Wang and Armstrong, 2012) , because spontaneous release can be mediated through independent pathways (Kavalali et al., 2011) .
If two mechanisms, for example, G␤␥/SNARE complex interactions and G␤␥/Ca 2ϩ channel interactions, coexist in one terminal, it raises fundamental questions about targeting of modulatory systems. Are G␤␥ effectors selectively targeted and, if so, are effector identities determined by G␤␥ properties or ultrastructurally with similar receptors and effectors as components of molecular machines? We demonstrate that two GPCRs, both G␣ i/o coupled, using membrane-delimited mechanisms and which both inhibit CA1 to subicular excitation modulate neurotransmitter release through different effectors whose targets are governed by the microarchitecture of SNARE complexes during vesicle priming.
Materials and Methods
Hippocampal slice preparation. Hippocampal slices (300 M thickness) were prepared from 17-to 23-d-old male Sprague Dawley rats anesthetized with isoflurane and decapitated in accordance with institutional guidelines. All recordings were in the following solution (mM): 124 NaCl, 26 NaHCO 3 , 1.25 NaH 2 PO 4 , 3 KCl, 2 CaCl 2 , 1 MgCl 2 , and 10 D-glucose, bubbled with 95% O 2 -5% CO 2 . Recordings were at 28°C maintained by a flow heating system of the superfusate, which was constantly superfused over the preparation at 1-2 ml/min for all recordings. All pharmacological agents applied extracellularly were added to the superfusate.
Electrophysiology. In hippocampal slices, CA1 and subicular pyramidal neurons were whole-cell clamped following microscopic visual identification under an upright microscope with the same lens used for imaging experiments. For postsynaptic subicular pyramidal cell recordings, patch pipettes (ϳ4 M⍀) contained solution of the following composition (in mM): 146 CsSO 3 , 2 MgCl 2 , 5 EGTA, and 9.1 HEPES, adjusted to pH 7.2 with CsOH. For imaging experiments recording from CA1 pyramidal neurons, the pipette composition was as follows (in mM): 146 KSO 3, 2 MgCl 2 , 0.025 EGTA, and 9.1 HEPES, adjusted to pH 7.2 with KOH. Dyes were included in the patch solution (Fluo-5F, 200 M; Alexa 594 hydrazide, 250 M). Series resistance was monitored throughout the experiment by application of a 5 mV voltage step and recordings were discarded if the series resistance changed by Ͼ10% during the course of the experiment. All holding potentials for whole-cell voltage-clamp recordings were at Ϫ70 mV. For current-clamp recordings the membrane potential was maintained between Ϫ70 and Ϫ80 mV. Liquid junction potentials were not corrected. EPSCs in subicular neurons were evoked with focal stimuli (0.2 ms, Ͻ20 A) to CA1 axons using glass-insulated tungsten microelectrodes.
Detection of spontaneous miniature EPSCs. Spontaneous miniature EPSCs (mEPSCs) and asynchronous events in Sr 2ϩ were low-pass filtered and digitized (5 kHz). Analysis was performed in Igor Pro (WaveMetrics). Detection and extraction of mEPSCs was semi-automated. Filtered data were differentiated to correct for baseline shifts. Thresholds were determined for differentiated control data and maintained for that cell following agonist application. Detected event amplitudes were mapped back onto raw data for visual comparison of amplitudes with mEPSCs to ensure that the detection algorithm functioned adequately. The algorithm is available from our website (http://alford.bios.uic.edu/Research/software.html). This algorithm was applied for asynchronous events in Sr 2ϩ . These events were detected over a time window (20 -300 ms poststimulus). Two-population KolmogorovSmirnov goodness-of-fit tests determined statistical significance in cumulative histograms. Data are expressed as means Ϯ SEM. Student paired two-tailed t tests were used to calculate significance, unless otherwise noted.
Imaging. Line-scan confocal imaging (500 Hz, modified Bio-Rad MRC 600 confocal scan head attached to a custom microscope, http://alford. bios.uic.edu/Research/software.html) was used for Ca 2ϩ transient recording in presynaptic varicosities following single action potentials stimulated with somatic whole-cell electrodes. Alexa 594 hydrazide was excited at 568 nm. Fluo-5F was separately excited (488 nm) and imaged in bandpass (510 -560 nm). Images were taken separately to ensure no cross-channel bleed-through. This was confirmed with neurons filled with only one dye. No bleed-through image was discernible for either dye to the incorrect channel. Varicosities were identified 20 -35 min after whole-cell access by imaging the Alexa 594 hydrazide dye and tracking the axon from the filled soma to its projection into the subiculum. Ca 2ϩ transients at these varicosities were imaged in line scanning mode (500 Hz) for up to 1 s during stimuli to the soma to evoke action potentials. Image analysis was performed within ImageJ except anatomical reconstructions (VoxBlast; VayTek). Line scan images are represented as linear with the applied LUT mapping.
G␤␥ competition binding assay. The open reading frames for the SNARE component proteins were subcloned into the pGEX6p1 vector (GE Healthcare) for expression in bacteria as previously described (Yoon et al., 2007) . To purify SNARE proteins, recombinant bacterially expressed glutathione S-transferase fusion proteins were expressed in Escherichia coli strain BL21(DE3). Protein expression was induced with 0.1 mM isopropyl ␤-D-thiogalactoside for 16 h at room temperature. Bacterial cultures were pelleted, washed with 1ϫ PBS, and then resuspended in lysis buffer [25 mM HEPES-KOH, pH 8.0, 150 mM KCl, 1 mM EDTA, 0.2 mM PMSF, 10.7 M leupeptin, 1.5 M aprotinin, 1 M pepstatin and 5 mM ␤-mercaptoethanol (BME)]. Cells were lysed with a sonic dismembrator at 4°C, 50% duty cycle, 20 s on, 40 s off, for 5 min total. GST-SNAP-25 and GST-H3 (the H3 domain of syntaxin1A) were purified from cleared lysates by affinity chromatography on glutathione Sepharose beads (GE Healthcare), following the manufacturer's instructions. While the proteins were bound to the beads, the beads were batch washed with two bed volumes of a buffer containing 25 mM HEPES-KOH, pH 8.0, 150 mM KCl, 1 mM EDTA, 1% Triton X-100, and 5 mM BME for 5 min at 4°C. This wash buffer was then exchanged with two bed volumes of a protease buffer containing 25 mM HEPES, pH 8.0, 150 mM KCl, 0.5% n-octyl ␤-D-glucopyranoside (OG), 10% glycerol, 1 mM EDTA, and 5 mM BME in a fresh tube for 5 min at 4°C. For GST-SNAP-25 on beads, the SNAP-25 was eluted by cleaving from GST with PreScission protease (GE Healthcare) overnight at 4°C in one bed volume of the protease buffer. Protein concentrations were determined with a Bradford assay kit (Pierce), and purity was verified by SDS/PAGE analysis.
For binary t-SNARE complex assembly a molar excess of 4 M SNAP-25 was mixed with 3 M GST-H3 on glutathione Sepharose beads in a buffer containing 25 mM HEPES, pH 8.0, 150 mM KCl, 0.25% OG, 10% glycerol, 5 mM BME, and 1 mM EDTA overnight at 4°C with gentle mixing. The binary t-SNARE complex was washed three times with protease buffer and eluted from the column by GST proteolytic cleavage with PreScission protease (GE Healthcare) for 4 h at 4°C as described above. Equimolar protein-protein interaction was confirmed by SDS-PAGE/ Coomassie staining analysis.
G␤ 1 ␥ 1 was purified from bovine retina as previously described (Mazzoni et al., 1991) . Fluorescence labeling of G␤ 1 ␥ 1 and binding assays were conducted as described previously (Phillips and Cerione, 1991) . Briefly, purified G␤ 1 ␥ 1 was dialyzed into labeling buffer (20 mM HEPES, pH 7.4, 5 mM MgCl 2 , 150 mM NaCl, and 10% Glycerol), then mixed with 2-(4Ј-Maleimidylanilino) naphthalene-6-sulfonic acid (MIANS) in a fivefold molar excess. The reaction proceeded for 3 h at 4°C before quenching with 5 mM 2-mercaptoethanol. The MIANS-G␤ 1 ␥ 1 complex was separated from unreacted MIANS using a PD-10 desalting column (GE Healthcare). MIANS-G␤ 1 ␥ 1 was stored in aliquots at Ϫ80°C.
Fluorescence measurements were performed in a fluorescence spectrophotometer (Cary Eclipse) at room temperature. Generally, MIANS-G␤ 1 ␥ 1 was diluted into 0.1 ml of assay buffer [20 mM HEPES, pH 7.5, 5 mM MgCl 2 , 1 mM dithiothreitol, 0.1 M NaCl, 1 mM EDTA] to a final concentration of 20 nM. The MIANS fluorescence was monitored at an excitation wavelength of 322 nm and emission of 417 nm. Fluorescence was normalized by expressing all data as (F 1 -F 0 )/F 0 (where baseline G␤␥-MIANS fluorescence mixed with t-SNARE ϭ F 0 , fluorescence after addition of synaptotagmin I ϭ F 1 ) All proteins purified as GST fusion proteins were cleaved from GST with PreScission protease (GE Healthcare) before analysis. The fluorescent changes caused by the addition of SNARE complexes were monitored continuously. Note that the amplitude of the fluorescence increase is not a measure of the affinity of the complex, but rather reflects the specific site on fluorescently labeled G␤␥ 
Results
Presynaptic GABA B and 5-HT 1B receptors inhibit CA1-subicular synaptic transmission To demonstrate that GABA B Rs and 5-HT 1B Rs inhibit neurotransmitter release from the same synapses, we stimulated CA1 pyramidal neuron axons in slices (Ͻ20 A, 200 s) and recorded postsynaptic responses in whole-cell voltage-clamped subicular pyramidal neurons (Fig. 1a) . The GABA A R and NMDA receptor antagonists (bicuculline, 5 M; D-2 amino-5-phosphonopentanoate, D-AP5, 50 M respectively) were applied to isolate AMPA receptor (AMPAR)-mediated EPSCs. We applied the selective 5-HT 1B R agonist CP93129 during whole-cell recordings, and the EPSCs were inhibited in a dosedependent manner (Fig. 1b, CP93129 ; 50 nM inhibited to 55 Ϯ 4% n ϭ 13; 400 nM to 37 Ϯ 3% p Ͻ 0.01, n ϭ 14; all significant p Ͻ 0.01). The GABA B R agonist, baclofen, similarly inhibited EPSCs profoundly ( Fig. 1c ; 1 M to 48 Ϯ 9% n ϭ 7; 10 M to 9 Ϯ 2% n ϭ 5; 100 M to 7 Ϯ 3%; all results significant, p Ͻ 0.01). Baclofen and CP93129 each inhibited synaptic transmission in every recording.
Further supporting a conclusion that 5-HT 1B Rs and GABA B Rs are functionally colocalized to the same terminals, the combination of intermediate concentrations of baclofen and addition of CP93129 did not cause a linearly additive inhibition of responses. Instead, responses remaining in baclofen (1 M) were inhibited by CP93129 (400 nM) significantly less effectively than in control (in 1 M baclofen, 400 nM CP93129 reduced the response to 67 Ϯ 9% of the response in baclofen; significantly less than the effect of CP93129 against control, p Ͻ 0.05; Fig. 1d ,e; n ϭ 7) This limited capacity to sum inhibitory effects indicates a convergence of targets; specifically that both receptors exist on the same presynaptic terminals. To confirm this, a further three experiments were performed in which a saturating dose of baclofen (10 M) was applied to inhibit an evoked EPSC, baclofen was washed from the superfusate, and a saturating dose of CP93129 (1 M) was applied (Fig. 1f ) . Baclofen inhibited the response to 11 Ϯ 5% of control; CP93129 subsequently inhibited the response to 24 Ϯ 8% of amplitude after wash of baclofen effects of both CP93129 and baclofen were significant ( p Ͻ 0.01). Because both agonists can inhibit the response by Ͼ50% these receptors must be present on the same presynaptic terminals.
GPCR activation and presynaptic Ca
2؉ entry Modulators of presynaptic Ca 2ϩ channels are key regulators of neurotransmission and GPCRs modulate presynaptic Ca 2ϩ entry Brown and Sihra, 2008) . Therefore, we measured presynaptic Ca 2ϩ transients in single presynaptic varicosities of CA1 neurons projecting to neurons in the subiculum, the main hippocampal output. To image single presynaptic varicosities, CA1 neurons were recorded in current clamp with patch electrodes containing Alexa 594 hydrazide (Alexa, 250 M) and a low affinity Ca 2ϩ indicator, Fluo-5F (200 M). After ϳ30 min of dye diffusion, cells were imaged and axons tracked to the subiculum using the red fluorescent dye Alexa 594 (Fig. 2a) . Single action potentials evoked by 2 ms depolarizing current pulses through the recording patch pipette caused presynaptic Ca 2ϩ transients in axon varicosities, which were line scanned while confocally imaging Fluo-5F ( Fig. 2b-e) . To ensure that Ca 2ϩ transients were unaffected by increasing dye/buffer concentration as it diffused into the axon, we recorded transients as the dye concentration increased. Values of baseline and peak increased f ) as the concentration of dye at the synapse increased (Fig. 2f,j ), but signals expressed as ⌬F/F remained constant with no change in peak amplitude of the response (Fig. 2e,i ) or of decay rate (Fig. 2e, h) , which is very sensitive to dye buffering capacity (Neher and Augustine, 1992; Jackson and Redman, 2003) . Thus, at 200 M, Fluo-5F buffering capacity is minimal compared with endogenous buffering and stably records action potential-induced presynaptic Ca 2ϩ transients (n ϭ 6 preparations). After recording control Ca 2ϩ transients, we applied a saturating dose of CP93129 (1 M, which reduces synaptic responses to Ͻ25% of control amplitudes), and imaged single action potential-evoked presynaptic Ca 2ϩ transients as above. CP93129 altered neither Ca 2ϩ entry (mean transient in CP93129 was 96 Ϯ 7% of control; Fig Fig. 3d ) with no change in variance after CP93129 application (mean variances before and after CP93129 were 0.037 Ϯ 0.012 and 0.038 Ϯ 0.013 (⌬F/F ) 2 ). We performed similar experiments with the GABA B R agonist baclofen ( Fig. 3e-h ). Baclofen slightly hyperpolarized the neuron (Fig. 3g) , however, stimuli always resulted in action potentials. Baclofen inhibited presynaptic Ca 2ϩ transients (to 56 Ϯ 7% of control, p Ͻ 0.05; Fig. 3e ,f; n ϭ 7). Each of the Ca 2ϩ transient events were recorded from one action potential in one presynaptic terminal, thus we can be certain that the Ca 2ϩ inhibition recorded was not due to action potential failure in a subset of axons, because each action potential evoked a corresponding presynaptic Ca 2ϩ transient. Indeed, in baclofen, no failure of presynaptic Ca 2ϩ transients was recorded; rather we recorded a reduction in amplitude of each evoked response (Fig. 3h) . While both baclofen and CP93129 inhibit exocytosis at this synapse, baclofen inhibits presynaptic Ca 2ϩ entry, whereas CP93129 does not.
The presynaptic target of 5-HT 1B receptors: spontaneous release Inhibition of presynaptic Ca 2ϩ entry by baclofen adequately explains its presynaptic inhibition should a fourth power relationship couple Ca 2ϩ entry to neurotransmitter release (Dodge and Rahamimoff, 1967) . Thus, if we take the fourth power of each of the Ca 2ϩ signals after baclofen (10 M) these would predict a reduction of the EPSC to 15 Ϯ 7% of control. This is not significantly different from the observed reduction of the EPSC amplitude recorded in baclofen (9 Ϯ 2% of control; 10 M; Fig. 1 ).
In contrast, 5-HT 1B Rs must inhibit neurotransmitter release by another mechanism. The equivalent fourth power of the Ca 2ϩ signal caused by CP93129 was to just 93 Ϯ 20% of control (significantly different from the effect on synaptic transmission; p Ͻ 0.05). Thus, 5-HT 1B Rs must inhibit release by a mechanism that does not cause a reduction in presynaptic Ca 2ϩ entry. One such mechanism was first identified at the neuromuscular junction, where adenosine inhibits ACh release by a Ca 2ϩ -independent mechanism that leads also to significant reductions in spontaneous neurotransmitter release (Silinsky, 1984 (Silinsky, , 2008 ). Thus, we tested whether 5-HT 1B Rs inhibit spontaneous release. mEPSCs were recorded in subicular neurons in tetrodotoxin (TTX; 1 M) to prevent evoked release, and D-AP5 (50 M) and bicuculline (5 M) to isolate AMPAR-mediated EPSCs before and during application of CP93129 (400 nM; n ϭ 6; Fig. 4a-d ). Events were detected as indicated (see Materials and Methods) and showed a very similar kinetic profile to evoked events (Fig. 4e) . The mean amplitudes and kinetic profiles of these events were compared before and during application of CP93129 (400 nM). CP93129 had no effect on amplitude (mean mEPSC amplitude in CP93129 was 99 Ϯ 6% of control) or kinetic profile of the events (Fig. 4f ) , demonstrating that the effect of agonist was not postsynaptic. Furthermore, the amplitude distribution and cumulative amplitude distributions (Fig. 4g ) before and in CP93129 were identical. Similarly the agonist had no effect on the frequency distribution or cumulative frequency distribution of the recorded events (frequency of events in CP93129 was 116 Ϯ 21% of control; Fig. 4h , significance of distributions was tested with two-sample Kolmogorov-Smirnov tests). Thus, in contrast to neuromuscular effects of adenosine (Silinsky, 1984) , 5-HT 1B Rs do not affect mEPSCs.
The lack of effect of 5-HT 1B R activation on spontaneous release is consistent with an inhibitory effect targeting an aspect of Ca 2ϩ -evoked exocytosis. As a comparison similar experiments Peak values of signal intensity and rate of response decay were obtained from single exponential fits to these data. e, The data in b-d were expressed as (⌬F/F ϩ 1) and overlaid. Colors from b-d. f, Graph demonstrating rise in intensity of Alexa 594 in this neuron's terminal over the time course of the experiment as the dye diffused into the terminal varicosities. g, Graph of decay rate (, left axis) and peak value of (⌬F/F ϩ 1) for this presynaptic varicosity during the experiment. h, Mean decay rate () and (i) the mean peak (⌬F/F ϩ 1) during the course of the experiments (n ϭ 6 preparations). j, Graph showing rise in intensity of Alexa 594 signal normalized to the first time point of recording in all terminals (same 6 preparations as h and i).
were performed on spontaneous release during the application of baclofen. Spontaneous mEPSCs were again recorded in subicular neurons in TTX (1 M), D-AP5 (50 M), and bicuculline (5 M) to isolate AMPAR-mediated EPSCs before and during application of baclofen (10 M; n ϭ 5; Fig. 4i-l ) . The mean amplitudes and kinetic profiles of these events were compared before and during application of baclofen, which had no effect on amplitude (mean mEPSC amplitude in baclofen was 106 Ϯ 17% of control) or kinetic profile of the events (Fig. 4m) or on the amplitude distribution and cumulative amplitude distributions (Fig. 4n) . Similarly baclofen had no effect on the frequency distribution or cumulative frequency distribution of the recorded events (frequency of events in baclofen was 94 Ϯ 22% of control; Fig. 4o ; significance of distributions were tested with two-sample Kolmogorov-Smirnov tests). Thus, neither GABA B Rs nor 5-HT 1B Rs modify spontaneous release, which occurs independently of Ca 2ϩ -entry through Ca 2ϩ channels and is likely activated by Doc2 rather than synaptotagmin I (Groffen et al., 2010; Pang et al., 2011) .
The presynaptic target of 5-HT 1B receptors: asynchronous release Baclofen may clearly inhibit neurotransmitter release by reducing presynaptic Ca 2ϩ entry. However, CP93129 and 5-HT 1B Rs do not modify presynaptic Ca 2ϩ signals and yet only act on Ca 2ϩ -evoked release. A second such mechanism by which GPCRs inhibit neurotransmitter release with no inhibitory effect on presynaptic Ca 2ϩ entry has been identified in lamprey synapses (Blackmer et al., 2001; Gerachshenko et al., 2005) , in amygdala (Delaney et al., 2007) , and in chromaffin cells (Blackmer et al., 2005) . G␤␥ inhibits release by a competitive interaction with synaptotagmin I at the C-terminal region of the SNARE complex (Yoon et al., 2007) . Synaptotagmin binds Ca 2ϩ to evoke vesicle fusion, and Ca 2ϩ -synaptotagmin I competes with G␤␥ at the C-terminal region of the SNARE complex in vitro, and in lamprey synapses (Blackmer et al., 2005; Gerachshenko et al., 2005; Yoon et al., 2007) . Substitution of Sr 2ϩ for Ca 2ϩ in the superfusate provides an approach to identifying whether G␤␥ interacts with this C-terminal region of the SNARE complex. Sr 2ϩ evokes asynchronous vesicle fusion following evoked entry through Ca 2ϩ channels (Mellow et al., 1978) but does not cause synaptotagmin to interact with SNARE complexes Bhalla et al., 2005) . Given that Sr 2ϩ enters through Ca 2ϩ channels and yet does not cause synaptotagmin SNARE interactions, it provides an independent approach to determine whether GPCRs act at Ca 2ϩ channels or via synaptotagmin I/SNARE complex interactions. Thus, we first determined whether Sr 2ϩ -synaptotagmin I competes with G␤␥ at SNARE complexes using a sensitive quantitative in vitro fluorescence assay (Phillips and Cerione, 1991; Yoon et al., 2007) . G␤ 1 ␥ 1 (20 nM assay concentration) was labeled with an environmentally sensitive probe, MIANS, which shows enhanced fluorescence in more hydrophobic local conditions, indicating interaction with a binding partner. The assay was used to quantify synaptotagmin I C2AB fragment competition with MIANS-labeled G␤␥ for binding to t-SNARE complexes comprising the syntaxin1A H3 domain and SNAP-25 in increasing concentrations of either Sr 2ϩ or Ca 2ϩ . We used a synaptotagmin I mutant (K326A, K327A) that exhibits wild-type SNARE binding affinity but which has a reduced propensity to oligomerize (Bai et al., 2004) . MIANS-G␤␥ fluorescence increases following interaction with t-SNARE complexes, but this increase is significantly reduced by 20 nM synaptotagmin I when applied in the presence of Ca 2ϩ (Yoon et al., 2007) . As a control, MIANS-G␤␥ does not show significant interactions with C2AB alone. Thus, we tested competition between G␤␥ and C2AB at t-SNARE complexes substituting Sr 2ϩ for Ca 2ϩ . The interaction between 20 nM MIANS-G␤␥ and 1 M t-SNARE complex was only slightly reduced by 20 nM C2AB in increasing Sr 2ϩ concentrations up to 250 M ( Fig. 5a ; normalized fluorescence reduced to 69.8 Ϯ 4.0% of the response in 0 Sr 2ϩ ). To confirm earlier results, the experiment was repeated with Ca 2ϩ and the effect with Sr 2ϩ was substantially and significantly less than that seen for 250 M Ca 2ϩ ( Fig.  5b; Figure 5a ). During recordings from subicular neurons in hippocampal slices, we replaced extracellular Ca 2ϩ with Sr 2ϩ . Synchronous EPSCs (stimulated as Fig. 1 ) were reduced in amplitude while asynchronous events typical of Sr 2ϩ (Mellow et al., 1982) were recorded (Fig. 5c,d ). Asynchronous events were detected from 20 ms poststimulus to the end of the sweep (Fig. 5c,d , shading; 40 control sweeps, 40 CP93129 sweeps). Time/frequency histograms of mean frequencies of events for all neurons revealed the event frequency distribution. CP93129 had no effect on this distribution nor on overall event frequency (frequency in CP93129, was 97 Ϯ 5% at 50 nM and 88 Ϯ 12% at 400 nM events in Sr 2ϩ alone; Fig. 5d ; n ϭ 7). Averaging detected events revealed that neither amplitudes nor kinetics of Sr 2ϩ -evoked asynchronous events were affected by CP93129 (Fig. 5d, inset) .
Baclofen substantially reduces presynaptic Ca 2ϩ entry to CA1 neuron terminals in the subiculum. Consequently, it may be used as a positive control to demonstrate the effect of inhibiting Ca 6%, n ϭ 5) and nearly eliminated them at a higher concentration (10 M; Fig.  5e ,f; to 21 Ϯ 12%, n ϭ 4), but had no effect on kinetics (Fig. 5f, inset) or the mean amplitude of asynchronous events that were detected (Fig. 5f, inset) . Contrasting inhibitions by baclofen and CP93129 on Sr 2ϩ -evoked release are most notable on asynchronous events. Even so, CP93129-mediated inhibition of the early EPSC in Sr 2ϩ was substantially less than in Ca 2ϩ (EPSC was 92 Ϯ 2% of peak in Sr 2ϩ at 50 nM CP93129 and 67 Ϯ 7% at 400 nM; Fig. 5 h; significantly less inhibition than in Ca 2ϩ , p Ͻ 0.01; reductions to 55 and 37%). In contrast to CP93129, inhibition by baclofen in Sr 2ϩ was similar to that in Ca 2ϩ (1 M baclofen peak EPSC reduced to 53 Ϯ 3% of amplitude in Sr 2ϩ , in 10 M baclofen reduced to 18 Ϯ 3%, n ϭ 6; Fig. 5i ). Even the small inhibition by CP93129 may be explained by residual Ca 2ϩ that cannot be removed (Xu-Friedman and Regehr, 1999) .
Similarly to effects on event frequencies, neither amplitudes nor the distribution of Sr 2ϩ -evoked asynchronous events were affected by CP93129. This was shown to help clarify that no postsynaptic effects of these receptors account for the observed inhibition. As for event frequency data (Fig. 5) , event amplitudes were plotted against time in a window from 20 to 300 ms after the stimulus ( Fig.  6a-d ; analysis of same data as Fig. 5 ; in all seven neurons mean event amplitude in 400 nM CP93129 was 108 Ϯ 5% of event amplitude in Sr 2ϩ alone). Time/amplitude histograms and cumulative plots of mean event amplitudes for all neurons were plotted to show no effect on the amplitude distribution of events by CP93129.
Similar analysis was performed for neurons recorded in an intermediate baclofen dose (1 M), at which sufficient numbers of events were detected. Event amplitudes were plotted across a similar time window in Sr 2ϩ and after addition of baclofen (1 M; Fig. 6e,f) . Time/amplitude histograms and cumulative plots of mean event amplitudes for all neurons showed no effect on the amplitude distribution of events by baclofen (Fig. 6 g,h) . The mean event amplitudes in baclofen (1 and 10 M) were 93 Ϯ 3 and 89 Ϯ 5%, respectively, of the amplitudes in Sr 2ϩ alone (n ϭ 5 and 4, respectively). These data also indicate that neither agonist modified the postsynaptic response to detected events.
Spontaneous mEPSCs in Ca 2ϩ -containing Ringer (Fig. 4) were unaffected by CP93129 as were events in Sr 2ϩ
. Furthermore, CP93129 was equally effective in in- (Fig. 5a ) to cause exocytosis Bhalla et al., 2005) .
The presynaptic target of 5-HT 1B receptors: BoNT/A cleavage of C-terminal SNAP-25
Because Sr 2ϩ does not recruit synaptotagmin I to evoke release and Sr 2ϩ -synaptotagmin does not compete effectively with G␤␥ at SNARE complexes, it is likely that 5-HT 1B Rs modify fusion by targeting the SNARE complex C-terminal region. Consequently, we investigated how 5-HT 1B R signal transduction interacts with this region of the SNARE complex. BoNT/A reduces presynaptic inhibition mediated by 5-HT via G␤␥ in lamprey (Gerachshenko et al., 2005) , noradrenaline in amygdala (Delaney et al., 2007) , and G␤␥ in PC12 cells (Blackmer et al., 2005) . BoNT/A cleavage of the C terminus of SNAP-25 favors synaptotagmin I/SNARE interactions over those with G␤␥ (Yoon et al., 2007) without preventing SNARE complex formation. Thus, we determined the effects of BoNT/A on CP93129-mediated presynaptic inhibition.
Hippocampal slices were incubated (2-4 h) in light/heavy chain BoNT/A (1-2 nM) to cleave the C-terminal 9 residues from SNAP-25. It remains unclear whether SNARE complex formation during priming might protect SNAP-25 from BoNT/A (Xu et al., 1998) , thus, we eliminated any residual primed vesicles unaffected by BoNT/A during the incubation period. Subicular pyramidal neurons were recorded as in Figure  1 and stimuli were applied to CA1 axons. Residual primed vesicles were eliminated by stimulation (400 stimuli, 1 Hz; Fig. 7a ). EPSCs were markedly depressed during the 1 Hz stimulation period, but partially recovered, albeit to a still significantly inhibited response (66.7 Ϯ 1% of control, p Ͻ 0.05, n ϭ 5; Fig. 7a ) when stimulation was slowed to 1/15 Hz. CP93129 applied to these reduced responses caused much less inhibition, indicating that 5-HT 1B R effectors target the SNARE complex (EPSC amplitudes were 77 Ϯ 5% of post 1 Hz amplitude; n ϭ 5, 50 nM, and 67 Ϯ 1%, 400 nM n ϭ 5; Fig. 7a,b) . This inhibition was significantly less than that seen in control recordings (Fig. 7e) .
To ensure that the 1 Hz prestimulation did not compromise CP93129-mediated inhibition, slices were treated as controls without BoNT/A. Four hundred stimuli (1 Hz, applied as before) caused less short-term depression (Fig. 7c) . EPSCs recovered to 82 Ϯ 1% of control at 1/15 Hz stimulation (Fig.  7c,d ). Subsequent application of CP9319 inhibited EPSCs to the same extent as it did in applications with no 1 Hz stimulation (for 50 and 400 nM to 46 Ϯ 4 and 34 Ϯ 6% of post 1 Hz amplitudes; Fig. 7c-e; n ϭ 3) . Thus, 5-HT 1B R-mediated inhibition is curtailed following SNAP-25 cleavage with BoNT/A. 5-HT 1B Rs inhibit release to a much reduced extent after cleavage of the C-terminal 9 residues of SNAP-25 and the subsequent elimination of previously primed vesicles and their associated SNARE complexes. However, while most BoNTs cannot access their SNARE complex target proteins after the formation of ternary SNARE complexes during vesicle priming (Hayashi et al., 1994; Pellegrini et al., 1994) , it is not clear whether this is true of BoNT/A. Indeed, following BoNT/A treatment, SNARE complexes can be formed, although with reduced efficacy at promoting vesicle fusion (Otto et al., 1995) . It was possible to determine whether BoNT/A, like other BoNTs, fails to access primed vesicle SNAREs or whether BoNT/A treatment alone caused nonspecific damage to the synapses leading to a loss of 5-HT 1B R-mediated effects. Slices were treated with BoNT/A as for Figure 7 . However, after BoNT/A treatment, no prestimulus train was given, thus leaving the primed vesicle pool intact before application of agonist. After obtaining controlevoked EPSCs at 15 s intervals, CP93129 reduced responses as for controls (to 29 Ϯ 3% at 400 nM; Fig. 8a,b) . Thus, consistent with a final target of the 5-HT 1B R on the primed vesicle (Gerachshenko et al., 2005) , the readily releasable pool must be depleted after BoNT/A treatment in order for BoNT/A to prevent 5-HT 1B R-mediated inhibition.
From results using Ca 2ϩ imaging, Sr 2ϩ -evoked asynchronous release, and BoNT/A it is clear that 5-HT 1B Rs target the SNARE complex to modify Ca 2ϩ -synaptotagmin binding, while GABA B Rs inhibit presynaptic Ca 2ϩ entry.
Selective targeting of G␤␥ effector targets and the SNARE complex GABA B Rs and 5-HT 1B Rs are colocalized in the same synaptic pathway between CA1 and subicular pyramidal neurons but inhibit exocytosis by different mechanisms. These mechanisms nevertheless both use G␤␥ subunits (Blackmer et al., 2001; Catterall and Few, 2008) . Ca 2ϩ channels may localize to the SNARE complex N terminus (Sheng et al., 1994 (Sheng et al., , 1996 , while 5-HT 1B R-liberated G␤␥ interacts with the SNARE complex C terminus (Blackmer et al., 2001 (Blackmer et al., , 2005 Yoon et al., 2007) . It is interesting that 5-HT 1B Rs do not, under normal circumstances, modulate presynaptic Ca 2ϩ while GABA B Rs do. We hypothesized that the SNARE complex separates receptor/effector complexes. To test this, we prevented SNARE complex formation by cleavage of syntaxin by applying BoNT/C (Hayashi et al., 1994) .
Recordings were made from CA1 pyramidal neurons in current-clamp mode. Similarly to Figures 2 and 3 , the electrodes were filled with Alexa 594 hydrazide (250 M) and the Ca 2ϩ indicator Fluo-5F (200 M). In addition, the electrodes contained light chain BoNT/C (5 nM), which was infused into CA1 neurons with the dyes. After 35 min of whole-cell recording to allow diffusion of the toxin and the dyes throughout the neuron and its axon, 200 action potentials (1 Hz) were evoked by short depolarizing current pulses (2 ms) through the patch electrode. This was done to eliminate any residual primed vesicles whose SNARE complexes are known to prevent BoNT/C access to its target, syntaxin (Hayashi et al., 1994) . Presynaptic varicosities were identified as in Figures 2 and 3 and subsequently line scanned with 488 nm excitation during single action potentials. The 5-HT 1B R agonist CP93129 (1 M; Fig. 9a,d ) now significantly inhibited Ca 2ϩ transients in all of the terminals recorded (to 52 Ϯ 7% of control amplitude n ϭ 8; not significantly different from the effect of baclofen under control conditions). Like baclofen, this inhibition was not due to a failure of action potentials to evoke presynaptic responses, because in all cases an identifiable Ca It has been demonstrated that preexisting G␤␥ modulation of Ca 2ϩ channels in expression systems is reduced by BoNT/C (Zamponi et al., 1997; Jarvis et al., 2000) . It is important to consider that in the latter experiments only the SNARE complex proteins, plus Ca 2ϩ channels and G␤␥, were present. Intact synapses, in contrast, represent a substantially more complex situation, in which BoNT/C in synapses cleaves syntaxin, but consequently prevents SNARE formation and further vesicle priming. Therefore, we determined whether pretreatment with BoNT/C modifies baclofen inhibition of Ca 2ϩ transients. In cells infused with BoNT/C and stimulated (200 action potentials) identically to experiments with CP93129, baclofen (10 M) inhibited presynaptic Ca 2ϩ transients similarly to controls without BoNT/C (to 55 Ϯ 6%, n ϭ 5, compared with 56 Ϯ 7% with no BoNT/C treatment; Fig.  9b,d) .
To ensure that BoNT/C treatment and subsequent action potential-evoked depriming did not alter the Ca 2ϩ transient amplitude, in a further three neurons recorded as above, Ca 2ϩ transients were evoked after loading of the terminal but before application of 200 action potential at 1 Hz. This response was compared with that obtained after the 1 Hz period of stimulation to remove any primed vesicles. No significant alteration in the Ca 2ϩ transient was seen (Fig.  9c,d ; response amplitude after 1 Hz stimulation was 96 Ϯ 3% of control. Decay rate of the transient was also similar: before 200 stimuli ϭ 154 Ϯ 29 ms, after 200 stimuli ϭ 147 Ϯ 30 ms).
In these presynaptic terminals, it is likely that GABA B Rs and 5-HT 1B Rs functionally colocalize within the same terminals. transients (orange, 200 stimuli after BoNT/C application, n ϭ 3; blue, CP93129, n ϭ 8; green, baclofen, n ϭ 7) both in Control conditions. Then after priming eliminated with BoNT/C (red, CP93129, n ϭ 5; dark green, baclofen, n ϭ 4). BoNT/C revealed reduction of Ca 2ϩ transients in CP93129. **p Ͻ 0.01.
For imaging experiments, all recorded terminals (n ϭ 12 in total) in which baclofen was applied alone showed inhibition of Ca 2ϩ entry, while after BoNT/C treatment all eight tested terminals showed inhibition of Ca 2ϩ entry by CP93129. The probability of randomly sampling only single receptor-expressing terminals would be extremely low ( p ϭ 0.0007 and p ϭ 0.004, for GABA B Rs and 5-HT 1B Rs, respectively) indicating coexpression of GABA B and 5-HT 1B receptors. Nevertheless, to confirm that both receptors are functional on the same presynaptic terminals four further Ca 2ϩ imaging experiments were performed in which BoNT/C was applied to the recorded neurons to test efficacy of both GABA B Rs and 5-HT 1B Rs on the same terminal. Neurons were again recorded with electrodes containing BoNT/C, Fluo-5F, and Alexa 594 hydrazide as above. In two of these neurons after identifying presynaptic varicosities, control Ca 2ϩ transients were recorded. Baclofen (1 M) was applied, transients recorded, and baclofen washed from the superfusate (Baclofen reduced responses to 68 and 86% of control). Following wash 200 stimuli were applied to exhaust the primed vesicle pool. CP93129 (1 M) was applied to test whether responses could be inhibited (responses were inhibited to 36 and 55% of the pre-CP93129 control response). In a further two experiments similar recordings were made. However, after identification of the presynaptic varicosity, 200 stimuli were immediately applied to exhaust the synaptic vesicle pool (Fig. 10a-c) . Control Ca 2ϩ transients were recorded and after CP93129 (1 M) was applied the responses were reduced to 58 and 56% of control. CP93129 has proved very difficult to wash from the superfusate, thus a high dose of baclofen (100 M) was applied to test whether a further reduction in the Ca 2ϩ transient could be recorded. Baclofen reduced the remaining responses by a further 58 and 75% of the responses in CP93129 (Fig. 10a,b) . Baclofen caused a slight hyperpolarization of the recorded neuron; however, this did not prevent the firing of a somatic action potential (Fig. 10c) , and in each case this action potential evoked a measurable Ca 2ϩ transient at the presynaptic varicosity, demonstrating no spike failure (Fig.  3h) . The CP93129 and baclofen-dependent inhibition of Ca 2ϩ transients at the same presynaptic varicosities confirms that GABA B Rs and 5-HT 1B Rs are found at the same synapse (Fig.  10d) .
Discussion
GPCR-mediated inhibition of neurotransmitter release at presynaptic terminals (Starke, 1972) is considered ubiquitous (de Jong and Verhage, 2009 ). However, GPCRs may inhibit release by a number of mechanisms. In this study we have demonstrated two such mechanisms mediated by distinct G␣ i/o -coupled receptors that coexist on CA1 pyramidal neuron presynaptic terminals: GABA B R-mediated inhibition of Ca 2ϩ channels and 5-HT 1B Rmediated G␤␥ interaction with the SNARE complex. We propose that the SNARE complex itself segregates these signaling pathways (Fig. 10d) .
GPCRs can regulate neurotransmitter release by modifying presynaptic Ca 2ϩ entry (Wu and Saggau, 1995) by a membrane delim- ited action of G␤␥ on Ca 2ϩ channels (Herlitze et al., 1996; Tedford and Zamponi, 2006) or alternatively by pathways that neither alter, nor require Ca 2ϩ entry. These latter effects were first revealed by receptor-mediated inhibition of spontaneous release events (mEPSCs) independently of evoked Ca 2ϩ entry and have been identified in the peripheral and central nervous systems (Silinsky, 1984; Stephens, 2009 , 1997) . In hippocampus, GABA B Rs have been implicated in both effects within the CA3 region (Lei and McBain, 2003) . A third mechanism by which G␤␥ inhibits neurotransmitter release by directly interacting with the SNARE complex has also been identified. 5-HT 1B Rs (Blackmer et al., 2001; Takahashi et al., 2001) , noradrenergic ␣ 2A Rs (Delaney et al., 2007) , and mGluRs (Zhang et al., 2011; Upreti et al., 2013 ) may all act via this mechanism, which does not involve a change in presynaptic Ca 2ϩ entry. Instead G␤␥ acts directly in the pathway of Ca 2ϩ -evoked exocytosis by interfering with Ca 2ϩ -dependent synaptotagmin binding to SNARE complexes (Blackmer et al., 2001; Gerachshenko et al., 2005; Delaney et al., 2007; Yoon et al., 2007) .
G␤␥ interactions in the presynaptic terminal are modified by the release machinery itself. Membrane delimited actions of G␤␥ on Ca 2ϩ channels may be augmented by a direct interaction of G␤␥ with various release machinery proteins (Dunlap and Fischbach, 1978; Holz et al., 1989; Herlitze et al., 1996; Ikeda, 1996) . For example, SNARE complexes, Ca 2ϩ channels, and G␤␥ (Jarvis et al., 2002) may interact to augment G␤␥-mediated inhibition of Ca 2ϩ channels, while GPCR-mediated inhibition of Ca 2ϩ entry can be prevented by BoNT/C cleavage of syntaxin 1A in ciliary ganglion neurons (Stanley and Mirotznik, 1997). However, GPCRmediated Ca 2ϩ channel inhibition is also seen in heterologous expression systems such as COS-7 cells with no coexpression of SNARE complex proteins and in isolated membrane patches with no presynaptic structures (Meir et al., 2000) , indicating that formation of a complex with SNARE proteins is not required for modulation. Another presynaptic protein, cysteine string protein, can also augment G␤␥-mediated voltage-dependent inhibition of Ca 2ϩ channels (Magga et al., 2000) while the ancillary Ca 2ϩ channel subunits (Ca v ␤) promote voltage-dependent Gprotein modulation of Ca 2ϩ channels (Dresviannikov et al., 2009 ). Perhaps any one of these or other protein-protein interactions may predispose Ca 2ϩ channels to be modulated by G␤␥. Of these, interaction with intact syntaxin 1A is one, but clearly structural relationships with other proteins are essential for GPCR modulation of Ca 2ϩ channels. In this study we show that GABA B Rs substantially modulate Ca 2ϩ transients in hippocampal nerve terminals, even after cleavage of syntaxin 1A by treatment with BoNT/C.
It is less clear whether interacting proteins are necessary for G␤␥ to inhibit neurotransmitter release by its direct, but Ca 2ϩ -synaptotagmin-dependent, action on the SNARE complex (Blackmer et al., 2001; Takahashi et al., 2001 ). This inhibition involves competition between G␤␥ and synaptotagmin for binding to the SNARE complex, and has been characterized by sensitivity to BoNT/A toxin (Blackmer et al., 2005; Gerachshenko et al., 2005; Delaney et al., 2007; Zhang et al., 2011) , which alters the relative affinities of Ca 2ϩ -synaptotagmin and G␤␥ to the SNARE complex (Yoon et al., 2007) .
5-HT 1B Rs clearly inhibit release from CA1 neurons by using this direct interaction with the SNARE complex (Fig. 10d) . The evidence for this comes from a number of results that we have presented in this study. 5-HT 1B Rs strongly inhibit neurotransmitter release with no effect on presynaptic Ca 2ϩ entry measured directly from individual presynaptic terminals. 5-HT 1B R-mediated inhibition is prevented by pretreatment with BoNT/A, which modifies competition between G␤␥ and Ca 2ϩ -synaptotagmin at the C-terminal region of SNARE complexes. We also show that, in contrast to GABA B Rs, these receptors do not modify Sr 2ϩ -evoked release. This is significant because, unlike Ca 2ϩ as shown in this study and in earlier work (Bhalla et al., 2005) , Sr 2ϩ does not cause synaptotagmin binding to SNARE complexes leaving no direct target for G␤␥ to interfere with exocytosis. Together with earlier work indicating that G␤␥ can compete with Ca 2ϩ -dependent synaptotagmin binding to the C-terminal region of the SNARE complex (Blackmer et al., 2005; Gerachshenko et al., 2005; Yoon et al., 2007; Wells et al., 2012) , these data imply that 5-HT 1B Rs cause a direct interaction of G␤␥ on SNARE complexes. Finally, 5-HT 1B Rs do not modify spontaneous event frequencies. However, the receptor clearly interferes with Ca 2ϩ -dependent release-albeit not by altering Ca 2ϩ entry but instead by altering the interaction of Ca 2ϩ -synaptotagmin with the SNARE complex. These data also indicate that G␤␥ and Doc2, a proposed mediator of spontaneous release (Groffen et al., 2010; Pang et al., 2011) , do not share a binding site on SNARE complexes. G␤␥ interacts with the very C-terminal region of SNAP-25, overlapping the C-terminal region of the synaptotagmin I interaction site (Blackmer et al., 2005; Yoon et al., 2007; Wells et al., 2012) . Perhaps Doc2 interacts at a less C-terminal region of the SNARE complex (Groffen et al., 2010) . Since Sr 2ϩ -evoked asynchronous release is also likely mediated by Doc2 (albeit different isoforms; Pang et al., 2011), and not synaptotagmin I, this could also explain why 5-HT 1B R has no effect on asynchronous release.
The effect of GABA B Rs is much simpler. These receptors substantially inhibit Ca 2ϩ (and Sr 2ϩ ) entry to the presynaptic terminal. GABA B Rs inhibit Ca 2ϩ entry sufficiently to account for baclofen's effect on EPSCs if a fourth power relationship couples Ca 2ϩ to exocytosis (Dodge and Rahamimoff, 1967) . We propose that functional separation of these pathways is provided by a microarchitecture, by which we mean G␤␥ prefers its nearest effector, as determined by the location of the associated GPCRs within the active zone. In synapses, Ca 2ϩ channels may localize to SNARE complex N terminus (Jarvis et al., 2000 (Jarvis et al., , 2002 . GPCRs, particularly GABA B Rs (Padgett and Slesinger, 2010), form molecular machines by complexing with effectors and downstream targets, including Ca 2ϩ channels (Park et al., 2010) . Indeed, the GB1 GABA B R subunit C-terminal region is required for the receptor to associate with Ca 2ϩ channels and to fully inhibit neurotransmitter release (Laviv et al., 2011) . Similarly, in the case of 5-HT 1B Rs (Svenningsson et al., 2006) , association of the receptor to molecular targets is required for functional inhibition of neurotransmitter release. G␤␥, liberated by 5-HT 1B Rs, targets SNARE complex C-terminals to inhibit release (Blackmer et al., 2001 (Blackmer et al., , 2005 Gerachshenko et al., 2005) . This result places effectors of 5-HT 1B Rs and GABA B Rs at opposite ends of primed SNARE complexes, and this separation appears to be sufficient to confer G␤␥ specificity.
Perhaps SNARE complexes functionally separate targets of G␤␥. G-protein or GPCR interactions with the SNARE complex may prevent 5-HT 1B R-mediated G␤␥ release from interacting with Ca 2ϩ channels but not GABA B R released G␤␥. Physical disruption of this microarchitecture by cleavage of syntaxin and subsequent disruption of vesicle priming with BoNT/C reveals equally effective targeting of Ca 2ϩ channels by both receptors (Fig. 10e) . Thus, receptor selectivity to their respective targets is not necessarily a property of a particular G␤␥ isoform, but may be a function of the structure in which the signal transduction cascade is embedded. BoNT/C treatment has also been previously shown to modify Ca 2ϩ entry to presynaptic terminals (Bergsman and Tsien, 2000; Degtiar et al., 2000) , albeit at a much slower time course than recorded in this study. It is conceivable that an alteration of the nanodomains of Ca 2ϩ channels may also alter their availability to G␤␥ in the terminal. However, the loss of primed vesicles by stimulation after BoNT/C application did not alter Ca 2ϩ entry, and the effect of baclofen on this Ca 2ϩ entry was also not altered by BoNT/C treatment. When 5-HT 1B Rs and their effector G␤␥ are no longer anchored to their target at the C-terminal region of the SNARE complex G␤␥ may inhibit presynaptic Ca 2ϩ channels. Similarly, presynaptic Ca 2ϩ channels will also no longer be associated with SNARE complexes (Fig.  10d,e) . Of course, ultimately, properties of this signal transduction system must govern its target during vesicle priming. These results do not exclude the possibility that G␤␥ identity plays a role in effector targeting. Indeed, there is precedent for such specificity (Macrez-Leprêtre et al., 1997; Wu et al., 1998; Mahon et al., 2006) . If formation of primed SNARE complexes ensures G-protein target specificity, then priming must take just milliseconds to recruit modulatory proteins to the correct region of the SNARE complex as it is formed.
